With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia ...

In separate announcements Wednesday, a pair of agencies shared business updates both aimed at leveling up their respective ...

Brexafemme (ibrexafungerp) partners GSK and Scynexis have worked out their quarrel related to a clinical trial that was previously put on hold, leaving Scynexis with a $22 million payout. | Through ...

Codis, born from the fusion of U.S.-based Particle Dynamics and a U.K. | In addition to substantial spray drying capacity, ...

GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...

Sometimes, an agency’s staffing needs can lead to the discovery of a new passion. | In a Q&A for Fierce Pharma Marketing’s ...

In a statement, Cabaletta CEO Steven Nichtberger, M.D., highlighted Gavel’s previous experience commercializing cell ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. | Halozyme scoured very broadly for ...

It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time ...

With the launch of a new branded initiative, Bristol Myers Squibb is crafting a recipe for both ramping up its Cobenfy ...

State privacy laws are reshaping the way pharmaceutical companies reach patients, said Katie Carr, chief revenue officer at ...